دورية أكاديمية
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy
| العنوان: | Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy |
|---|---|
| المؤلفون: | Gardner, Sharon L, Tarapore, Rohinton S, Allen, Jeffrey, McGovern, Susan L, Zaky, Wafik, Odia, Yazmin, Daghistani, Doured, Diaz, Zuanel, Hall, Matthew D, Khatib, Ziad, Koschmann, Carl, Cantor, Evan, Kurokawa, Ryo, MacDonald, Tobey J, Aguilera, Dolly, Vitanza, Nicholas A, Mueller, Sabine, Kline, Cassie, Lu, Guangrong, Allen, Joshua E, Khatua, Soumen |
| المساهمون: | Oncoceutics, NCI SBIR-Bridge, Making Headway Foundation, Fly A Kite Foundation |
| المصدر: | Neuro-Oncology Advances ; volume 4, issue 1 ; ISSN 2632-2498 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | General Medicine |
| الوصف: | Background ONC201, a dopamine receptor D2 (DRD2) antagonist and caseinolytic protease P (ClpP) agonist, has induced durable tumor regressions in adults with recurrent H3 K27M-mutant glioma. We report results from the first phase I pediatric clinical trial of ONC201. Methods This open-label, multi-center clinical trial (NCT03416530) of ONC201 for pediatric H3 K27M-mutant diffuse midline glioma (DMG) or diffuse intrinsic pontine glioma (DIPG) employed a dose-escalation and dose-expansion design. The primary endpoint was the recommended phase II dose (RP2D). A standard 3 + 3 dose escalation design was implemented. The target dose was the previously established adult RP2D (625 mg), scaled by body weight. Twenty-two pediatric patients with DMG/DIPG were treated following radiation; prior lines of systemic therapy in addition to radiation were permitted providing sufficient time had elapsed prior to study treatment. Results The RP2D of orally administered ONC201 in this pediatric population was determined to be the adult RP2D (625 mg), scaled by body weight; no dose-limiting toxicities (DLT) occurred. The most frequent treatment-emergent Grade 1-2 AEs were headache, nausea, vomiting, dizziness and increase in alanine aminotransferase. Pharmacokinetics were determined following the first dose: T1/2, 8.4 h; Tmax, 2.1 h; Cmax, 2.3 µg/mL; AUC0-tlast, 16.4 hµg/mL. Median duration of treatment was 20.6 weeks (range 5.1-129). Five (22.7%) patients, all of whom initiated ONC201 following radiation and prior to recurrence, were alive at 2 years from diagnosis. Conclusions The adult 625 mg weekly RP2D of ONC201 scaled by body weight was well tolerated. Further investigation of ONC201 for DMG/DIPG is warranted. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/noajnl/vdac143 |
| DOI: | 10.1093/noajnl/vdac143/45812953/vdac143.pdf |
| الإتاحة: | https://doi.org/10.1093/noajnl/vdac143Test https://academic.oup.com/noa/article-pdf/4/1/vdac143/46855431/vdac143.pdfTest |
| حقوق: | https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.CE28C0AB |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/noajnl/vdac143 |
|---|